GSK (LON:GSK) Insider Julie Brown Acquires 6 Shares

GSK plc (LON:GSK) insider Julie Brown bought 6 shares of the company’s stock in a transaction dated Tuesday, February 10th. The stock was bought at an average cost of GBX 2,179 per share, with a total value of £130.74.

GSK Price Performance

GSK stock traded down GBX 15 during mid-day trading on Wednesday, reaching GBX 2,153. The company had a trading volume of 121,524,398 shares, compared to its average volume of 12,884,935. The business has a fifty day simple moving average of GBX 1,861.08 and a 200 day simple moving average of GBX 1,682.05. The company has a market cap of £86.87 billion, a P/E ratio of 16.19, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. GSK plc has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 2,219.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities research analysts predict that GSK plc will post 175.980975 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th. Berenberg Bank lifted their price objective on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research note on Monday, November 24th. Citigroup increased their target price on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research report on Monday. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a research report on Wednesday, January 7th. Finally, UBS Group reiterated a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a research report on Friday, January 23rd. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of GBX 1,917.86.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.